Source Post

Top Pharma Stocks: Deep Dive with a Former Worker Part 1

The creator, a former pharmaceutical industry insider, discusses the sector's challenges, particularly the impact of Medicare negotiating lower drug prices. While generally avoiding pharma stocks, he will analyze popular companies under duress, starting with Novo Nordisk and its drug Ozempic, highlighting the potential for reduced revenue due to price cuts.

Linked Mentions

Tickers discussed in this post

Linked Signals

Tracked calls opened from this post

No linked signals were opened directly from this post.